News | August 13, 2021
JB Chemicals & Pharmaceuticals PAT at Rs. 118.9 cr for Q1 FY22
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
Demand normalisation post the second wave contributed to the steady growth
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
Wastewater surveillance is becoming increasingly critical for community health monitoring for detecting COVID-19 outbreaks and the spread of other infectious diseases
The collaboration will support Canada with direct access to rapid pandemic response capabilities
A new market study published by Global Industry Analysts (GIA), released its report titled, ``Healthcare Supply Chain Management—Global Market Trajectory & Analytics.’’ We present excerpts from the report
The company has also applied to DCGI for Emergency Use Authorization (EUA) for ZyCoVD, the world's first Plasmid DNA Vaccine
Company working on COVID vaccine INO 4800
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
Subscribe To Our Newsletter & Stay Updated
